

**MARKET PROFILE**

Ticker (NASDAQ): **ATEC**  
 Price: **\$5.34**  
 52-Week Range: **\$1.10 - \$5.51**  
 Shares Outstanding: **52.5 million**  
 Average Daily Volume: 118,546  
 Market Capitalization: **\$280.4 million**  
 (data as of December 31, 2009)



**ANALYST COVERAGE**

**California Equity Research**  
Bud Leedom

**Canaccord Adams**  
William Plovnic


**Deutsche Bank Securities**  
Tao Levy

**Noble Financial**  
Jan Wald

**RBC Capital Markets**  
Glenn Novarro

**Roth Capital Partners**  
Matt Dolan

**Quarterly Revenues**



**Solutions for the Aging Spine**



Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven design that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis and other aging spine diseases, improved minimally invasive products and techniques, and integrated biologic solutions. In addition to its US operations, the Company also markets its spine products in Europe. In Asia, the Company markets a broad line of spine and orthopedic products through its subsidiary, Alphatec Pacific, Inc.

**ALPHATEC SPINE AGREES TO ACQUIRE SCIENT'X GROUPE SAS**

Acquisition creates global scale and offers revenues and cost synergies, complements Alphatec Spine's product portfolio and enhances Aging Spine Focus combined entity to be third-largest global pure-play spinal implant company.

**PERFORMANCE HIGHLIGHTS FOR Q3 2009**

- Record consolidated revenue of \$32.7 million reported in the third quarter 2009, which represents 27% growth over the third quarter 2008.
- Adjusted EBITDA reached \$3.6 million in the third quarter 2009, reflecting strong operating leverage.
- Reiterating 2009 guidance of \$128 million to \$130 million and adjusted EBITDA guidance of \$12.5 million to \$14.5 million. Reaffirming EPS guidance of EPS positive by the fourth quarter of 2009.

**ALPHATEC SPINE GROWTH DRIVERS**

- Gain market share in the core US spinal fusion business
- Own the 'aging spine' market
- Leverage product line and manufacturing capacity through international expansion
- Expand US sales force to support product pipeline



# Robust Product Pipeline Driving Growth

Broad IP portfolio of approximately 40 patents and patent applications.

## EXECUTIVE TEAM

### Dirk Kuyper

President, Chief Executive Officer

### Peter C. Wulff

Chief Financial Officer,  
Vice President & Treasurer

### Ebun S. Garner, Esq.

General Counsel,  
Vice President & Secretary

### Gary Fredericks

Vice President, Corporate Accounts

### Kristine M. Jacques

Vice President, Product Marketing

### Peter Kohlbecher

General Manager – Europe

### Stephen A. Lubischer

Vice President, Sales

### Kermit P. Stott

Vice President, Operations

### JP Timm

Vice President, R&D

### Mitsuo Asai

President – Alphatec Pacific

## INVESTOR RELATIONS CONTACTS

### Peter C. Wulff

Chief Financial Officer

Alphatec Spine, Inc.

(760) 494-6746

[investorrelations@alphatecspine.com](mailto:investorrelations@alphatecspine.com)

### Lynn Pieper, CFA

Managing Director

Westwicke Partners

(415) 202-5678

[lynn.pieper@westwicke.com](mailto:lynn.pieper@westwicke.com)




Alphatec Spine  
is a proud  
Sponsor of the:



This document includes forward-looking statements that are based on certain assumptions made by us that we believe to be appropriate in the circumstances. Risks and uncertainties may cause our actual results to differ materially from those projected in these forward-looking statements. You can find a discussion of these factors and more information about us in our filings with the SEC.

## Product Introductions



## NEW PRODUCT HIGHLIGHTS



### Osseofix™ - Structural Kyphoplasty

Titanium implant mechanically restores and maintains height. Controlled placement and deployment. Creation of bone channels allowing cement interdigitation – no void creation.

EU market launch 4Q 2008

US 510(k) clinical study initiated

Pending 510(k) clearance, not available for sale in the US


## The Best Spine Technologies of 2009\*

### OsseoScrew - Pedicle Screw for Osteopenic Bone

Significantly increased pullout and holding strength, improved purchase in aging bone, can be used with or without bone cement.

Expected US market launch – Late 2009

Pending 510(k) clearance, not available for sale in the US



### GLIF/ARC Portal Access System

#### Guided Lumbar Interbody Fusion –

Breakthrough lateral approach through curved cannulae that does not require patient repositioning. Direct visualization of disc space via a proprietary portal system. Potential to reduce OR, trauma and recovery time.

Expand US market launch – 1Q 2010

\* 2009 Orthopedics This Week Spine Technology Awards

## AGING SPINE MARKET

### Demographics a Key Growth Driver

Over 65 population will more than double to 70+ million by 2030

### Aging Spine Disease States

Osteoporotic bone fractures, stenosis, acquired spondylolysis, adult deformity

### Significant Unmet Clinical Needs

Few products currently treat specific diseases of aging spine